SHANGHAI, April 2, 2026 /PRNewswire/ — Free tickets for 2026 Medtec open on April 1, 2026. Visitors who complete registration before August 31 can enter free of charge. As Asia’s Leading Medical Device Supply Chain Expo — From R&D to Commercial Manufacturing, 2026 Medtec will be held from September 1–3, 2026, at the Shanghai New International Expo Centre (SNIEC), Pudong, Halls N1–N4. On-site registration during the exhibition will incur a 100 RMB admission fee per person.

https://visitorreg.medteccn.com/medtec-en/?utm_medium=pressrelease&utm_source=prnewswire&utm_campaign=register_open&utm_content=en Visit the official website now to claim your free ticket and stay ahead in the industry!

Free Tickets Now Open (April 1 – August 31, 2026)

Free tickets are open through August 31, 2026, offering visitors a more efficient way to plan their visit to 2026 Medtec.

Early Registration Benefits:

• Free access (save up to 100 RMB per person)
• Support for international group registration
• Fast-track entry with no on-site queue
• Flexible visit scheduling

2026 Medtec Overview

Marking its 20th edition, Medtec continues to serve as a comprehensive platform across the full medical device R&D and manufacturing chain, with an exhibition area of 47,000 square meters, 1,100 exhibitors, and an estimated 93,000 visits.

The exhibition provides integrated solutions across R&D, prototyping, manufacturing, certification, mass production, OEM services, and CRO and CDMO capabilities. Exhibits span a wide range of categories, including materials, core components, electronic parts, optical components, surface processing, precision machining, automation equipment, packaging, sterilization, testing, and consulting services.

The exhibition will be organized across four halls at SNIEC, spanning N1-N4.The four halls are structured around key segments of the medical device supply chain, from materials and core components to manufacturing services and equipment.

Halls N1–N2 focus on Medical Materials & Core Components.

Hall N1 Highlights:

• Metal Materials and Their Components
• Orthopedic and Dental Implant Processing Zone
• Ceramics, Biomaterials, Glass, and Other Materials and Related Components
• Ultra-precision Laser Processing, Machine Tools and Additive Manufacturing

Hall N2 Highlights:

• Medical Rubber and Plastic Materials and Their Components
• Bonding Agents, Bonding Products
• IVD Reagents, Filtration, Intravenous Injection, and Laboratories
• Pipe Fittings and Extrusion
• Pharmaceutical Delivery Systems, Dressing Materials and Formulation Processing

Halls N3–N4 focus on Medical Manufacturing Service & Equipment.

Hall N3 Highlights:

• Plastic Film Molding Services and Equipment
• OEM/ODM Contract Manufacturing Services
• Medical Automation, Drive Control, Robotics, Smart Factory
• Pipe Fittings and Extrusion Equipment
• Surface Treatment

Hall N4 Highlights:

• Medical Packaging, Sterilization, Labeling, Cleanroom
• R&D and Design, Software Services, and Consulting Services
• Exhibition of Testing, Metrology, Inspection and Calibration Equipment and Supplies
• Integrated Service Area

Visitor Composition

Medtec’s core visitor base includes medical device manufacturers, supply chain companies, and import-export enterprises. Attending representatives span senior executives, directors, engineers, managers, supervisors, and specialists. Their responsibilities cover management, R&D and technical centers, process and manufacturing engineering, quality, supply chain and procurement, as well as regulatory affairs.

It also attracts professionals from hospitals, clinics, and public health institutions, including hospital administrators, department directors and deputy directors, attending physicians, and other healthcare personnel. In addition, researchers and professors from research institutes and universities in medical device-related fields are expected to attend, alongside investors and analysts from the healthcare sector.

2026 Medtec will continue to attract participation from the industry’s top buyer companies.

Conclusion

As a key platform for leading companies to launch new products and showcase cutting-edge technologies, Medtec brings together a full spectrum of materials, components, manufacturing equipment, and supporting services. It supports one-stop sourcing while helping global companies connect with the China market.

Free tickets for 2026 Medtec open on April 1 and close on August 31, 2026 — register in advance to secure free admission.

Media Contact

Website: https://en.medtecchina.com/

Talia Li, talia.li@informa.com 

Booth Enquiry: LINC, +86 21 6157 7217, linc.cai@informa.com

Visitor and Media Enquiry: Tracy, +86 10 6562 3307, tracy.zhang@informa.com

Taiwan’s Leading Distillery Wins WWA’s Highest Honour as Two Expressions Advance to Finals

TAIPEI, April 2, 2026 /PRNewswire/ — Taiwan’s trailblazing whisky distillery, Kavalan, has achieved a landmark moment at the World Whiskies Awards (WWA) 2026, one of the most respected competitions in the global whisky industry. Kavalan was named Distiller of the Year, securing the highest global honour and reaffirming its position among the world’s leading whisky producers.

This first-time achievement is a huge jump from Kavalan’s previous titles of Distiller of the Year – Rest of World, signalling Kavalan’s evolution from a regional standout into a global benchmark.

King Car Chairman Mr. YT Lee said Kavalan was honoured to be recognised at the World Whiskies Awards, widely regarded as one of the most prestigious and rigorous competitions in the global whisky industry.

“Among international competitions, the WWA is considered a true benchmark for excellence, and we are deeply humbled to receive this top honour. This recognition is not only a proud moment for Kavalan, but also for Taiwan, reflecting our team’s dedication to craftsmanship and quality. This marks Kavalan’s nineteenth distillery award of the highest industry honours in the twenty years since its founding. We remain committed to upholding these values and sharing Kavalan’s unique character with whisky lovers around the world.”

Kavalan’s Distiller of the Year title at the Icons of Whisky Awards 2026, marking a historic first for the distillery in this highest global honour. The award further affirms the distillery’s exceptional whisky-making capabilities, with its craftsmanship, cask expertise, and flavour finesse earning high praise from the judging panel. The distillery has demonstrated remarkable growth in visitor experience, brand storytelling, product innovation, and sustainability initiatives, while strengthening corporate responsibility, reinforcing its position as a global benchmark for excellence in whisky production.

This year, two Kavalan expressions advanced to the final stage of the competition, with Kavalan Peatist Oloroso Sherry Cask Single Cask Strength Single Malt Whisky and Kavalan Distiller’s Reserve No.1 Single Malt Whisky both named WWA 2026 winners for Taiwan in their respective categories.

Organized by Whisky Magazine, the World Whiskies Awards was launched in 2007 and widely regarded as one of the most authoritative competitions in the global whisky industry. This year, thousands of entries from 46 countries and regions were evaluated through a rigorous three-stage blind tasting process by a distinguished panel of experts, including leading journalists, specialist retailers, distillers, and industry professionals.

About World Whiskies Awards

With an unwavering commitment to excellence, the World Whiskies Awards selects, rewards, and promotes outstanding whiskies, showcasing the mastery of distillers in flavour, complexity, and character. Each category undergoes rigorous evaluation by a panel of judges with exceptional expertise and discerning palates. The Icons of Whisky recognise the people and places whose work is the foundation of the whisky industry.

About Kavalan Whisky

Kavalan Distillery in Yilan County has been pioneering the art of single malt whisky in Taiwan since 2005. Our whisky, aged in intense humidity and heat, sources the crystal meltwaters of Snow Mountain and is enhanced by sea and mountain breezes. These conditions combine to create Kavalan’s signature creaminess. Taking Yilan County’s old name, our distillery is backed by more than 45 years of beverage-making under parent company, King Car Group. We have collected over 950 gold awards or higher from the industry’s most competitive contests.

CONTACT:

Kaitlyn Tsai
kaitlyn@kingcar.com.tw  

Wendy Wang
wendywa@kingcar.com.tw  

SHANGHAI, April 2, 2026 /PRNewswire/ — The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. The evening, co-hosted by Founding Platinum Sponsor Wilson Sonsini and the BayHelix Group, recognized outstanding achievements in healthcare investment, financing, and deal-making over the past year.

This year’s awards honored the companies and individuals at the forefront of China’s dynamic healthcare sector — from landmark licensing and partnership agreements to capital markets milestones and private financings that are reshaping the industry. Award recipients were selected through a formal vote conducted by CHIC’s Founders and 2026 Organizing Committee & Working Group, whose collective expertise spans venture capital, private equity, and global healthcare leadership.

Award Winners

IPO of the Year

Winner: Insilico Medicine
Accepted by: Leah Liu, VP and Global Head of IR & Capital Markets, Insilico Medicine
Presenter: Richard Wang, China Partner, Wilson Sonsini

Private Financing of the Year — Tied

Co-Winner: Kailera Therapeutics
Accepted by: Shelley Liu, Head of China Business Development & Strategy, Hengrui (Kailera Therapeutics was built on Hengrui assets)
Presenter: Kan Chen, Co-Head of Healthcare, Qiming Venture Partners

Co-Winner: Vor Bio
Accepted by: Jianmin Fang, CEO, RemeGen (Vor Bio’s leading project is from RemeGen)
Presenter: Cyber Cao, Managing Director, HSG

Deal of the Year — Tied

Co-Winner: Hengrui Pharma – GSK
Accepted by: Shelley Liu, Head of China Business Development & Strategy, Hengrui; and Ming Fang, PhD, Senior Director, Search & Evaluation, Business Development, GSK
Presenter: Steve Yang, Co-Founder, the BayHelix Group; Co-CEO, WuXi Apptec

Co-Winner: Innovent – Takeda
Accepted by: Sophy Wang, Board Secretary & Global BD, Innovent; and Eric Yeung, Head of Oncology and Global Business Development, Takeda
Presenter: Kevin Yuan, CEO, Hankang Capital

About CHIC 2026

The China Healthcare Investment Conference (CHIC) is a premier platform connecting innovation and investment in China’s healthcare sector. Now in its 12th year, CHIC brings together senior decision-makers including venture capital and private equity investors, pharmaceutical executives, and biotech and medtech CEOs. The 2026 conference was held on March 23–24 at The Ritz-Carlton Hotel Pudong, Shanghai, under the theme “Innovation in Healthcare – The Answer to Uncertainty.”

About the Gala Dinner Co-Hosts

Wilson Sonsini is a leading legal advisor to life sciences, and biotechnology industries, offering integrated counsel across the full spectrum of a company’s life cycle —  from early-stage intellectual property strategy and patent prosecution to complex technology transactions, licensing, collaborations, as well as M&As, IPOs and capital market offerings. As Founding Platinum Sponsor of CHIC, Wilson Sonsini has been a steadfast partner in the conference’s mission to connect healthcare innovation with global capital.

The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix serves as a co-host of the CHIC Gala Dinner and is a longstanding partner in advancing the global development of China’s healthcare sector.

CHIC 2026 Founding Individuals & Organizing Committee / Working Group

The following individuals served as the voting body for the CHIC 2026 Awards, representing the CHIC Founding Individuals and the Organizing Committee & Working Group.

Founders

Marietta Wu, Managing Director, Quan Capital
Frank Kung, Managing Partner, Vivo Capital
Hongbo Lu, Managing Member, NEXTBio Capital
James Li, Venture Partner, Frazier Lifesciences
Norman Chen, CEO, The Asian American Foundation

2026 Organizing Committee & Working Group

Cyber Cao, Managing Director, HSG
Jialing Dai, President & Publisher, PharmaDJ
Tess Cameron, Managing Director, RA Capital Management
Kan Chen, Co-Head of Healthcare, Qiming Venture Partners
Sean Zhang, Executive Director, Vivo Capital
Dandan Dong, Venture Partner, TCGX
Anna Chen, Partner, Frazier Life Sciences
Yuan Yuan, Head of Platform Development, China, NEXTBio Capita
Zhanghang Yan, Vice President, Quan Capital
Yun Gao, Principal, Lilly Asia Ventures

TOKYO, April 2, 2026 /PRNewswire/ — GA technologies Co., Ltd. (Headquarters: Minato-ku, Tokyo; President, CEO: Ryo Higuchi; Stock Code: 3491; hereinafter referred to as the “Company”) announces that its AI real estate investment service, “RENOSY,” has launched an initiative to rebrand “Renters Warehouse” (operated by RW OpCo, LLC [Headquarters: United States], a Group company), as “RENOSY by Renters Warehouse.”

URL: https://www.renterswarehouse.com/

• Background and Outlook of the Brand Integration and Renewal

Since its founding in 2013, the Company has operated under its corporate philosophy:

“Spark excitement and inspiration by fusing technology with innovation to propel the world forward.” The Company’s core business is the AI real estate investment service “RENOSY,” which leverages technology to provide unique one-stop services for property purchase, management, and sale.

RW OpCo, LLC, founded in 2007, operates the real estate investment marketplace “Renters Warehouse.” Primarily serving individuals and institutional investors in the United States, the platform functions as an online marketplace and currently operates in 18 states and 31 locations across the country.

The Company completed the consolidation of RW OpCo, LLC as a subsidiary in March 2024 and began providing real estate services in the U.S. market.^[1] Since the fiscal year ending October 2025, the business has maintained strong performance, achieving quarterly profitability and growing rapidly to become the Company’s third pillar of profit.^[2]

The Company has now moved to rebrand its U.S. business from “Renters Warehouse” to “RENOSY by Renters Warehouse,” aiming to drive further growth in the U.S. market and maximize group synergies. Through the full-scale expansion of “RENOSY” in the U.S. market, the Company looks to promote the adoption of services that enable reliable, seamless, and optimal asset formation through real estate in the country.

The impact of this matter on the Company’s business results is insignificant.

• AI Real Estate Investment RENOSY

RENOSY is an AI real estate investment service that utilizes technology. Reliable, seamless, and optimal asset-building through real estate is realized by providing one-stop support for the purchase, management, and sale of property, maximizing operational effectiveness. An extensive product lineup is offered that includes condominiums, apartments, and detached houses, etc. Surveys conducted by Tokyo Shoko Research have ranked RENOSY No. 1 in Japan in real estate investment sales and purchases.^[3]

• Profile of GA technologies

Company name: GA technologies Co., Ltd.
Representative: Ryo Higuchi, Representative Director, President and CEO
URL: https://www.ga-tech.co.jp
Headquarters: Sumitomo Fudosan Roppongi Grand Tower 40F, 3-2-1 Roppongi, Minato-ku, Tokyo
Established: March 2013

Businesses:

• Development and operation of AI real estate investment service “RENOSY”
• Development and operation of real estate B-to-B platform “ITANDI”
• Development of platform businesses in the PropTech domain

Major Group Companies: A total of 30 companies, including ITANDI Inc., RW OpCo, LLC, etc. Additionally, there are 28 subsidiaries under RW OpCo, LLC.

Please contact us if you have any questions about the release GA technologies Co., Ltd. PR contact point: pr@ga-tech.co.jp 

At Japan IT Week Spring 2026, Enabling IEC 62443-4-1–Aligned Security and Real-Time Intelligence Across Connected Infrastructure

TOKYO, April 2, 2026 /PRNewswire/ — SINTRONES Technology Corp. (TWSE: 6680), a global provider of rugged embedded and Edge AI computing solutions, will present its IEC 62443-4-1–aligned Edge AI platforms at Japan IT Week Spring 2026 (Tokyo Big Sight, West Hall 4, Booth W25-25). The showcase highlights how Edge AI supports real-time processing, system reliability, and cybersecurity across smart manufacturing, mobility, and mission-critical applications.

“Edge AI is becoming a core enabler of next-generation infrastructure,” said Kevin Hsu, CEO of SINTRONES Technology. “By aligning with IEC 62443-4-1 and focusing on reliability in harsh environments, we support secure and stable AI deployment at the edge across industrial automation, transportation, and mission-critical systems.”

At the exhibition, SINTRONES will present integrated Edge AI scenarios combining hardware platforms with real-world applications. In factory automation, the ABOX-5221 ThermoSiphon™ Edge AI computer, powered by the latest Intel® Core™ processors, delivers stable, high-performance AI inference for precision control. It features fanless ThermoSiphon™ liquid cooling, a backup battery unit for up to 10 minutes of emergency power, a MXM/M.2 dual module architecture for flexible AI acceleration, and dual 10GbE Ethernet for high-speed, redundant transmission, ensuring reliable, real-time operation in harsh industrial environments.

For defense and ISR applications, the ultra-compact IBOX-604-G2, weighing about 0.3 kg, enables real-time sensor fusion and on-device AI processing in drones and unmanned systems where size, weight, and power constraints are critical.

In transportation and mobility infrastructure, the IBOX-650P-IP66 will be showcased for deployment in railway and roadside environments. It features an IP66-rated enclosure, M12 IP67 connectors, and GMSL-2 camera support, designed for stable operation under vibration and outdoor conditions. Target applications include fleet management, passenger information systems, and real-time monitoring.

SINTRONES’ platforms are developed under a secure development lifecycle aligned with IEC 62443-4-1. In parallel, the company aligns with the Intel® AI and Edge ecosystem, leveraging optimized compute architectures and AI acceleration capabilities to support efficient, real-time processing at the edge. This approach enables customers to accelerate AI adoption while maintaining performance, interoperability, and long-term scalability across connected industrial systems.

About SINTRONES
Founded in 2009, SINTRONES Technology Corp. (TWSE: 6680) is a global provider of rugged industrial and Edge AI computing solutions. The company designs modular, certified platforms that enable real-time decision-making at the edge for mission-critical applications across transportation, industrial automation, and military and defence environments. For more info, please visit www.sintrones.jp

MELBOURNE, Australia and INDIANAPOLIS, April 2, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 2026^[1]. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED.

Mr. Gill is a life sciences executive with over 35 years’ experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical (including radiopharmaceuticals) and medical device companies. He currently serves on the boards of Evolus, Inc. (NASDAQ: EOLS), Allucent LLC, Bridge to Life Ltd, RapidPulse Inc. and huMannity Medtec (formerly Alfred Mann Foundation), and was until recently a board member of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Strongbridge Biopharma plc (NASDAQ: SBBP), Alpha Source Inc, Healthtronics, Inc, and Perimetrics, LLC.

Mr. Gill brings deep expertise in capital markets, scaling businesses, governance and corporate turn-around strategy and has served as Chief Financial Officer or President of multiple publicly traded companies, including EndoChoice Holdings, Inc. (NYSE: GI, acquired by Boston Scientific), INC Research (NASDAQ: INCR, now Syneos Health), and CTI Molecular Imaging (NASDAQ: CTMI, acquired by Siemens). He holds a B.S. in Accounting from Wake Forest University and an MBA from Emory University.

Telix Interim Chair, Mark Nelson, commented, “We are pleased to welcome David to the Board, where his strong financial expertise and deep knowledge of U.S. capital markets will be highly valuable. We intend to further strengthen the Board through additional appointments aligned with our growth trajectory and governance needs as a dual-listed company.”

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2026 Telix Pharmaceuticals Limited. All rights reserved.